+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of cefaclor



Evaluation of cefaclor



American Journal of Hospital Pharmacy 38(1): 54-58



The chemistry, pharmacology, pharmacokinetics, bacterial spectrum, clinical use, dosage, adverse reactions, and dosage forms and cost of cefaclor are reviewed. Cefaclor, a congener of cephalexin monohydrate, is a new semisynthetic cephalosporin antibiotic. It is well absorbed when given orally on an empty stomach; absorption is delayed by the presence of food. Although metabolism may play a role in the disposition of cefaclor, elimination is primarily renal. Cefaclor's spectrum of activity is similar to that of cefalexin, including a wide range of gram-negative and gram-positive bacteria; in particular, Escherichia coli, Klebsiella spp., Proteus mirabilis, Salmonella spp., and Haemophilus influenzae are more susceptible to clinically achievable concentrations of cefaclor than cephalexin. Cefaclor has been demonstrated to be effective against beta-lactamase-producing H. influenzae resistant to ampicillin, but further studies are needed to establish the clinical significance of this activity. Efficacy of cefaclor has been demonstrated in urinary tract, upper and lower respiratory tract, and skin and soft tissue infections in adults and children as well as in pediatric otitis media. Adverse reactions, mostly gastrointestinal, are generally mild and occur in few patients. Usual doses are 250-500 mg every eight hours in adults and 20--40 mg/kg/day in children, although this pediatric dose may be two low for otitis media. Clinical superiority of cefaclor over less expensive antibiotics has not been demonstrated.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 043045486

Download citation: RISBibTeXText

PMID: 7011003


Related references

Bioequivalence evaluation of two brands of cefaclor 500 mg capsules: quantification of cefaclor using solid phase extraction technique. Journal of Clinical Pharmacy and Therapeutics 26(2): 149-153, 2001

Clinical evaluation of S6472 (prolonged action preparation of cefaclor) in the treatment of skin and soft tissue infections. A double blind comparison of S6472 and cefaclor. Japanese Journal of Antibiotics 38(10): 2716-2734, 1985

Clinical evaluation of sustained release preparations of cefaclor in dental infections. Comparative double blind clinical studies of sustained release preparations with a regular preparation of cefaclor. Japanese Journal of Antibiotics 38(4): 1117-1140, 1985

Experience with cefaclor in the treatment of ear, nose and throat infections. Indications for cefaclor therapy. Infection 7 Suppl 6: 609-614, 1979

Recognition of allergenic determinants to cefaclor in patients with cefaclor-induced anaphylaxis. Journal of Allergy & Clinical Immunology 113(2 Supplement): S73, February, 2004

A multicentre trial of cefaclor advanced formulation versus cefaclor in the treatment of acute bronchitis. Postgraduate Medical Journal 68 Suppl 3: S24-8, Discussion S29, 1992

Heterogeneity of the IgE response to allergenic determinants of cefaclor in serum samples from patients with cefaclor-induced anaphylaxis. Annals of Allergy, Asthma & Immunology 94(6): 700-704, 2005

Separation of cefaclor and delta-3-cefaclor by micellar electrokinetic chromatography. Journal of Liquid Chromatography & Related Technologies 25(5): 731-746, March, 2002

Cefaclor advanced formulation versus cefaclor in the treatment of pneumonia. Clinical Therapeutics 14(4): 570-577, 1992

Cefaclor AF versus cefaclor in acute exacerbations of chronic bronchitis. Postgraduate Medical Journal 68 Suppl 3: S30-6; Discussion S36-7, 1992

Cefaclor in the treatment of upper respiratory tract bacterial infections in children. A comparative trial of cefaclor/cefalexin. Annales de Pediatrie 27(6): 405-408, 1980

Double-masked, randomized, parallel-group comparison of cefaclor AF and cefaclor in the treatment of acute bacterial sinusitis. Current Therapeutic Research. 58(4): 227-239, 1997

A double blind comparative study on s 6472 a long acting cefaclor versus conventional cefaclor preparation in complicated urinary tract infections. Japanese Journal of Antibiotics 43(11): 1873-1892, 1990

Pharmacological evaluation of cefaclor in volunteers. Antimicrobial Agents and ChemoTherapy 14(3): 454-456, 1978